Open AccessPrognostic, predictive, and surrogate factors for individualizing treatment for men with castration-resistant prostate cancer.
Author(s) -
Rhonda L Bitting,
Andrew J Armstrong
Publication year - 2012
Publication title -
american society of clinical oncology educational book. american society of clinical oncology. annual meeting
Language(s) - English
Resource type - Journals
ISSN - 1548-8748
DOI - 10.14694/edbook_am.2012.32.292
With the surge in therapeutic options for castration-resistant prostate cancer (CRPC) comes increasingly complicated treatment decision making, highlighting the need for biomarkers that can identify appropriate patients for specific treatments and accurately assess disease response. Here we discuss existing and potential prognostic, predictive, and surrogate biomarkers in CRPC.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom